Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People’s Republic of ...
Concord Medical Services Holdings Limited (NYSE: CCM) is a China-focused healthcare services company that operates radiotherapy and diagnostic imaging facilities. The company’s core operations are centered on delivering cancer treatment and diagnostic services through an established network of centers and specialty cancer hospital offerings. In business terms, Concord Medical combines ...Concord Medical Services Holdings Limited (NYSE: CCM) is a China-focused healthcare services company that operates radiotherapy and diagnostic imaging facilities. The company’s core operations are centered on delivering cancer treatment and diagnostic services through an established network of centers and specialty cancer hospital offerings. In business terms, Concord Medical combines clinical service delivery with supporting operational services that help hospitals and physicians coordinate care, including developing treatment protocols, supporting joint diagnosis, and providing clinical research-related support.
From a product and service perspective, the company’s offerings span multiple modalities used in oncology pathways. In radiotherapy, it provides treatment capabilities that include linear accelerator and external beam radiotherapy services, proton therapy systems, and radiosurgery platforms such as gamma knife. In diagnostics, it offers imaging services using modalities such as PET-CT and MRI. Beyond direct clinical delivery, the company supports hospitals via radiotherapy and diagnostic equipment leasing, equipment management services, and premium cancer/proton treatment services. It also provides teleconsultation and medical information technology services, which are intended to extend specialist expertise and coordinate care across sites.
The company reports business segments commonly described as “Network” and “Hospital.” The “Network” model reflects operating radiotherapy and diagnostic imaging centers, while “Hospital” reflects involvement in specialty cancer hospital operations, typically encompassing radiation, imaging, testing laboratory capabilities, inpatient/nursing services, and related oncology workflows. This service mix indicates a relatively integrated approach across diagnosis, treatment, and ongoing clinical operations.
Regarding cost structure and “BOM”-like considerations (materials and capital inputs), radiotherapy and imaging are capital-intensive, relying on sophisticated medical equipment (e.g., radiation delivery systems and imaging scanners) and specialized clinical staffing. While the provided dataset does not list specific bill-of-materials items, the operational economics of such centers typically involve capital depreciation/amortization, maintenance, consumables for imaging and treatment delivery, and personnel costs for radiation oncologists, medical physicists, imaging technologists, nurses, and support staff. Additionally, leasing and management services suggest the company can monetize access to equipment through contractual arrangements rather than solely owning all assets.
Financially, the supplied snapshot data indicates profitability pressures, with negative operating/EBIT/EBITDA/net profit margins in the latest trailing-twelve-month (TTM) view (e.g., gross margin around 6.9% and operating profit margin around -40.9%). Liquidity indicators provided also suggest constrained current liquidity (current ratio below 1 in the dataset) and relatively low solvency ratio values. These metrics imply that the business may be in a period where costs, utilization, pricing, reimbursement dynamics, or investment cycles influence earnings.
In terms of key people, Dr. Jianyu Yang serves as Chairman and Chief Executive Officer (and president) and has been in that leadership role since 2007, positioning him as the central executive figure guiding strategy and operations. With headquarters in Beijing, China, and an employee count of about 610, Concord Medical fits the scale of a mid-sized healthcare services operator managing specialized clinical sites and associated support functions.
Overall, Concord Medical’s “wish” or strategic direction is consistent with being a leading provider of oncology-related radiotherapy and imaging services in China—expanding and operating clinical capacity, enhancing technology platforms, and supporting hospitals and physician networks through integrated clinical support, information technology, and equipment-related services.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$460.5M
+19.9%
+96.3%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-92.8M
+69.9%
-96.3%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+5.6%
+127.2%
-0.0%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-52.0%
+62.5%
-2606.9%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-20.2%
+74.9%
+0.0%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-293.2M
+63.7%
—
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-63.7%
+69.8%
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
-172.8%
-0.3%
0.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
0.48x
+4.1%
0.0%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.